Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ABOS

Acumen Pharmaceuticals

ABOS Lead: Phase 2 7 Biotech Distilled articles ↓ 34 filings & releases ↓ Cash $53.1M (Sep 30, 2026) ↓ 7 verdicts ↓ 3 timing quotes ↓
Neurology Protein

Market cap $16.2M 72.3M shares (10-Q, Oct 21, 2026) × $0.224 close Nov 6, 2026

Most recent annual filing: 2026-01-15

Pipeline (4 active programs)

Technology platforms

EBD · JCR Pharmaceuticals

Enhanced Brain Delivery — BBB-penetrating, transferrin receptor (TfR)-targeted antibody delivery platform developed with JCR Pharmaceuticals; focus area: Alzheimer's disease, targeting toxic amyloid beta oligomers; enables subcutaneous administration via low-volume devices; preclinical candidate data announced early 2026; lead candidate IND filing targeted mid-2027

Targets: amyloid beta oligomers, AβOs, transferrin receptor, TfR, hTfR

ENHANZE · Halozyme

Halozyme's proprietary drug delivery technology used for subcutaneous formulation of sabirnetug; focus area: Alzheimer's disease.

Enhanced Brain Delivery · JCR Pharmaceuticals

Blood-brain barrier-penetrating antibody delivery technology utilizing transferrin-receptor targeting; focus area: Alzheimer's disease. Acumen collaborating with JCR Pharmaceuticals; IND filing for lead clinical candidate targeted for mid-2027.

Targets: transferrin receptor, amyloid beta oligomers

Capital (as filed)

Cash
$53.1M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$25.5M Sep 30, 2026
Operating cash flow
−$26.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$78.6M cash per the update of Oct 30, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (7)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (7 calls)

Every verdict Biotech Distilled has published on Acumen Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-02-18 Watch Acumen Pharmaceuticals (ABOS): Scientific Deep Dive for Sabirnetug Science is sound but the $50M ATM overhang and early-2027 cash cliff create structural dilution pressure; wait for the dilution to clear before entering.
  2. 2026-03-21 Buy core UPDATE: Acumen Pharmaceuticals (ABOS) - The Dilution Gap Closes, Smart Money Enters, and the Science Delivers The dilution gap resolved via a premium PIPE to RA Capital, NHP data confirmed 12-fold brain penetration for the EBD program, and insider buying reversed — the thesis played out and ABOS is now a high-conviction opportunity into the late-2026 Phase 2 readout.
  3. 2026-03-28 Buy core UPDATE: Acumen Pharmaceuticals (ABOS) - 10-K Drop: The Dilution Gap is Officially Closed Audited 10-K confirms runway extended into H2 2027 post-PIPE, eliminating pre-catalyst dilution risk and leaving ABOS as a fully funded pure-play binary event on the late-2026 Phase 2 readout.
  4. 2026-07-15 Buy core UPDATE: Acumen Pharmaceuticals (ABOS) - The EBD Data Just Got Better ACU401 delivered 40-fold brain exposure in primates with no anemia signal and preserved AβO selectivity, materially strengthening the EBD platform and the M&A case while the stock has not moved.
  5. 2026-08-13 Speculative buy speculative UPDATE: Acumen Pharmaceuticals (ABOS) - The Dilution Gap Re-Opens A going-concern warning, $110M cash against an annualizing ~$110-130M burn, and amortizing 14.6% debt re-open the dilution gap; the clinical thesis is unchanged but the financing floor has been withdrawn, making this a lottery ticket again.
  6. 2026-10-27 Speculative buy speculative UPDATE: Acumen Pharmaceuticals (ABOS) - The Clock Is Set, and So Is the Raise ALTITUDE-AD topline is now pinned to November 2026, cash is $78.6M with going-concern flag intact, and a $500M shelf lines up a post-data raise; this is a pure binary lottery ticket — hold into the readout.
  7. 2026-10-30 Avoid UPDATE: Acumen Pharmaceuticals (ABOS) - The Coin Landed on Tails ALTITUDE-AD missed the primary endpoint at both doses with no meaningful difference from placebo; sabirnetug is discontinued, wind-down costs and senior debt stand between remaining cash and shareholders, and the EBD program targets a now-failed mechanism.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (34)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)